The Effects of Cocoons of Larinus Hedenborgi (Coleoptera: Curculionidae) Extracts on Inflammation and Clinical Outcomes in Patients With Coronavirus Disease 2019: A Double-Blinded Randomized Controlled Clinical Trial

IF 1.5 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Current Therapeutic Research-clinical and Experimental Pub Date : 2025-01-01 DOI:10.1016/j.curtheres.2025.100811

Mahdi Keshani , Sayid Mahdi Mirghazanfari , Naseh Pahlavani , Faezeh Baniyaghoobi , Vahid Hadi , Mohammad Bagherniya , Zahra Heidari , Amirhossein Sahebkar , Mohsen Mohajeri , Saeid Hadi

{"title":"The Effects of Cocoons of Larinus Hedenborgi (Coleoptera: Curculionidae) Extracts on Inflammation and Clinical Outcomes in Patients With Coronavirus Disease 2019: A Double-Blinded Randomized Controlled Clinical Trial","authors":"Mahdi Keshani , Sayid Mahdi Mirghazanfari , Naseh Pahlavani , Faezeh Baniyaghoobi , Vahid Hadi , Mohammad Bagherniya , Zahra Heidari , Amirhossein Sahebkar , Mohsen Mohajeri , Saeid Hadi","doi":"10.1016/j.curtheres.2025.100811","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Severe acute respiratory syndrome coronavirus 2, the causative agent of coronavirus disease 2019 (COVID-19), is an inflammatory disease that manifests with symptoms including dry cough, fever, myalgia, and even pneumonia. Despite antiviral treatments, no definitive therapy has been proven effective. <em>Trehala manna</em> (TM), the edible cocoon of <em>Larinus hedenborgi</em> (Coleoptera: Curculionidae) weevil, as a natural product, is traditionally used to alleviate respiratory symptoms because of its antibacterial, anti-inflammatory, and antifungal properties.</div></div><div><h3>Objective</h3><div>The current study aimed to determine the effects of TM add-on treatment on inflammatory biomarkers and some clinical outcomes in patients with COVID-19.</div></div><div><h3>Methods</h3><div>The present study was a randomized controlled trial conducted on 60 patients who were randomly allocated to TM (5 g, twice a day) or a placebo for 1 week. The main outcomes of the current study include C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), blood urea nitrogen level, creatinine level, fasting blood sugar level, systolic blood pressure, and visual analog scale (VAS) score for cough, which were evaluated at both the beginning and end of the study.</div></div><div><h3>Results</h3><div>Our finding revealed that CRP level, ESR, blood urea nitrogen level, creatinine level, fasting blood sugar level, systolic blood pressure, and VAS score for cough were significantly reduced in the TM group after intervention (<em>P</em> < 0.05), and CRP level, ESR, VAS score for cough, and fever were significantly reduced in the TM group compared with the control after 7 days (<em>P</em> < 0.05).</div></div><div><h3>Conclusions</h3><div><em>Trehala mann</em> is a natural remedy with potential as an adjunctive therapy for reducing inflammatory biomarkers and improving certain clinical symptoms in patients with COVID-19. No adverse effects were observed during the trial. Iranian Registry of Clinical Trials identifier: IRCT20211029052904N1.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"103 ","pages":"Article 100811"},"PeriodicalIF":1.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Therapeutic Research-clinical and Experimental","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0011393X25000360","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Severe acute respiratory syndrome coronavirus 2, the causative agent of coronavirus disease 2019 (COVID-19), is an inflammatory disease that manifests with symptoms including dry cough, fever, myalgia, and even pneumonia. Despite antiviral treatments, no definitive therapy has been proven effective. Trehala manna (TM), the edible cocoon of Larinus hedenborgi (Coleoptera: Curculionidae) weevil, as a natural product, is traditionally used to alleviate respiratory symptoms because of its antibacterial, anti-inflammatory, and antifungal properties.

Objective

The current study aimed to determine the effects of TM add-on treatment on inflammatory biomarkers and some clinical outcomes in patients with COVID-19.

Methods

The present study was a randomized controlled trial conducted on 60 patients who were randomly allocated to TM (5 g, twice a day) or a placebo for 1 week. The main outcomes of the current study include C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), blood urea nitrogen level, creatinine level, fasting blood sugar level, systolic blood pressure, and visual analog scale (VAS) score for cough, which were evaluated at both the beginning and end of the study.

Results

Our finding revealed that CRP level, ESR, blood urea nitrogen level, creatinine level, fasting blood sugar level, systolic blood pressure, and VAS score for cough were significantly reduced in the TM group after intervention (P < 0.05), and CRP level, ESR, VAS score for cough, and fever were significantly reduced in the TM group compared with the control after 7 days (P < 0.05).

Conclusions

Trehala mann is a natural remedy with potential as an adjunctive therapy for reducing inflammatory biomarkers and improving certain clinical symptoms in patients with COVID-19. No adverse effects were observed during the trial. Iranian Registry of Clinical Trials identifier: IRCT20211029052904N1.

Abstract Image

查看原文本刊更多论文

Hedenborgi Larinus茧提取物对2019冠状病毒病患者炎症和临床结局的影响：双盲随机对照临床试验

严重急性呼吸综合征冠状病毒2是2019冠状病毒病（COVID-19）的病原体，是一种炎症性疾病，其症状包括干咳、发烧、肌痛甚至肺炎。尽管有抗病毒治疗，但尚无确切的治疗方法被证明有效。甘露海藻（Trehala manna， TM）是一种天然产物，是黑登博吉（Larinus hedenborgi）象鼻虫的可食用蚕茧，由于其抗菌、抗炎和抗真菌的特性，传统上被用于缓解呼吸道症状。目的本研究旨在确定TM加药治疗对COVID-19患者炎症生物标志物和一些临床结局的影响。方法本研究是一项随机对照试验，60例患者随机分配给TM （5 g，每天2次）或安慰剂，为期1周。本研究的主要结局包括c反应蛋白（CRP）水平、红细胞沉降率（ESR）、血尿素氮水平、肌酐水平、空腹血糖水平、收缩压、咳嗽视觉模拟量表（VAS）评分，并在研究开始和结束时进行评估。结果干预后TM组CRP水平、ESR、血尿素氮水平、肌酐水平、空腹血糖水平、收缩压、咳嗽VAS评分均显著降低（P < 0.05），干预后7 d TM组CRP水平、ESR、咳嗽VAS评分、发烧评分均显著低于对照组（P < 0.05）。结论strehala mann是一种天然药物，具有降低COVID-19患者炎症生物标志物和改善某些临床症状的辅助治疗潜力。试验期间未观察到不良反应。伊朗临床试验注册中心标识：IRCT20211029052904N1。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Therapeutic Research-clinical and Experimental 医学-药学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics. CTR encourages and supports the submission of manuscripts describing: • Interventions designed to understand or improve human health, disease treatment or disease prevention; • Studies that focus on problems that are uncommon in resource-rich countries; • Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing); • Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English; • Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.